Bek Smith的个人主页 - 老虎社区

Bek Smith

Bek Smith

暂无个人介绍

IP属地：海外

76关注

3粉丝

1主题

0勋章

2022-12-06

👍👍👍

2022-12-05

👍👍👍👍

2022-12-04

👍

2022-12-04

👍

2022-11-29

👍

思路迪申请通过香港IPO发行1635万股股票

2022-11-29

👍

抱歉，原内容已删除

2022-11-29

👍

《新股消息》3D MEDICINES-B(01244.HK)今起招股一手入场费13,252.23元

2022-11-29

👍

【新股IPO】3D MEDICINES-B(01244)今起招股入场费13252.23港元

2022-11-29

👍

新股发售 | 3D MEDICINES-B今起招股，入场费13252.23港元

2022-11-22

Woow going cool🔥😀

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4130472326487360","uuid":"4130472326487360","gmtCreate":1667369439139,"gmtModify":1667525469923,"name":"Bek Smith","pinyin":"beksmithbeksmith","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/da802faf6741ad7a08c0290f82b414cc","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":3,"headSize":76,"tweetSize":12,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":1,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":1,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.07.30","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.12.27","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.11.23","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":1,"location":"海外","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":629384276,"gmtCreate":1670270184796,"gmtModify":1670270186308,"author":{"id":"4130472326487360","authorId":"4130472326487360","name":"Bek Smith","avatar":"https://static.tigerbbs.com/da802faf6741ad7a08c0290f82b414cc","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4130472326487360","idStr":"4130472326487360"},"themes":[],"htmlText":"👍👍👍","listText":"👍👍👍","text":"👍👍👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/629384276","isVote":1,"tweetType":1,"viewCount":2394,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":629990197,"gmtCreate":1670182306119,"gmtModify":1670182307678,"author":{"id":"4130472326487360","authorId":"4130472326487360","name":"Bek Smith","avatar":"https://static.tigerbbs.com/da802faf6741ad7a08c0290f82b414cc","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4130472326487360","idStr":"4130472326487360"},"themes":[],"htmlText":"👍👍👍👍","listText":"👍👍👍👍","text":"👍👍👍👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/629990197","isVote":1,"tweetType":1,"viewCount":2413,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":629052879,"gmtCreate":1670121696591,"gmtModify":1670121698074,"author":{"id":"4130472326487360","authorId":"4130472326487360","name":"Bek Smith","avatar":"https://static.tigerbbs.com/da802faf6741ad7a08c0290f82b414cc","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4130472326487360","idStr":"4130472326487360"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/629052879","isVote":1,"tweetType":1,"viewCount":2167,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":629052153,"gmtCreate":1670121682273,"gmtModify":1670121683778,"author":{"id":"4130472326487360","authorId":"4130472326487360","name":"Bek Smith","avatar":"https://static.tigerbbs.com/da802faf6741ad7a08c0290f82b414cc","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4130472326487360","idStr":"4130472326487360"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/629052153","isVote":1,"tweetType":1,"viewCount":1607,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":620879931,"gmtCreate":1669691002723,"gmtModify":1669691006678,"author":{"id":"4130472326487360","authorId":"4130472326487360","name":"Bek Smith","avatar":"https://static.tigerbbs.com/da802faf6741ad7a08c0290f82b414cc","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4130472326487360","idStr":"4130472326487360"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/620879931","repostId":"2287354144","repostType":2,"repost":{"id":"2287354144","kind":"news","pubTimestamp":1669674367,"share":"https://www.laohu8.com/m/news/2287354144?lang=zh_CN&edition=full","pubTime":"2022-11-29 06:26","market":"sh","language":"zh","title":"思路迪申请通过香港IPO发行1635万股股票","url":"https://stock-news.laohu8.com/highlight/detail?id=2287354144","media":"媒体滚动","summary":"思路迪（3D Medicines）在港交所公告称，申请通过香港IPO发行1635万股股票，股票发行价指导区间为每股22.96-26.24港元，预计12月15日将开始交易。","content":"<html><body><p>思路迪（3D Medicines）在港交所公告称，申请通过香港IPO发行1635万股股票，股票发行价指导区间为每股22.96-26.24港元，预计12月15日将开始交易。</p></body></html>","source":"sina_symbol","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>思路迪申请通过香港IPO发行1635万股股票</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n思路迪申请通过香港IPO发行1635万股股票\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-11-29 06:26 北京时间&nbsp;&nbsp;&nbsp;<a href=https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/7x24/2022-11-29/doc-imqmmthc6355254.shtml><strong>媒体滚动</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>思路迪（3D Medicines）在港交所公告称，申请通过香港IPO发行1635万股股票，股票发行价指导区间为每股22.96-26.24港元，预计12月15日将开始交易。</p>\n\n<a href=\"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/7x24/2022-11-29/doc-imqmmthc6355254.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IPO":"Renaissance IPO ETF","01244":"思路迪医药股份"},"source_url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/7x24/2022-11-29/doc-imqmmthc6355254.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2287354144","content_text":"思路迪（3D Medicines）在港交所公告称，申请通过香港IPO发行1635万股股票，股票发行价指导区间为每股22.96-26.24港元，预计12月15日将开始交易。","news_type":1,"symbols_score_info":{"01244":1,"IPO":1}},"isVote":1,"tweetType":1,"viewCount":2677,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":620870264,"gmtCreate":1669690966158,"gmtModify":1669690967697,"author":{"id":"4130472326487360","authorId":"4130472326487360","name":"Bek Smith","avatar":"https://static.tigerbbs.com/da802faf6741ad7a08c0290f82b414cc","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4130472326487360","idStr":"4130472326487360"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/620870264","repostId":"2287453885","repostType":2,"isVote":1,"tweetType":1,"viewCount":3110,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":620870130,"gmtCreate":1669690916320,"gmtModify":1669690919930,"author":{"id":"4130472326487360","authorId":"4130472326487360","name":"Bek Smith","avatar":"https://static.tigerbbs.com/da802faf6741ad7a08c0290f82b414cc","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4130472326487360","idStr":"4130472326487360"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/620870130","repostId":"2287545465","repostType":2,"repost":{"id":"2287545465","kind":"news","pubTimestamp":1669681671,"share":"https://www.laohu8.com/m/news/2287545465?lang=zh_CN&edition=full","pubTime":"2022-11-29 08:27","market":"us","language":"zh","title":"《新股消息》3D MEDICINES-B(01244.HK)今起招股 一手入场费13,252.23元","url":"https://stock-news.laohu8.com/highlight/detail?id=2287545465","media":"AAFN","summary":"生物医药公司3D MEDICINES-B公布招股详情，拟全球发售1,635万股，香港公开发售占一成，国际发售占九成。招股价介乎每股22.96至26.24元。每手500股计，一手入场费13,252.23元。该股今日起招股，下周三中午截止，预期将于12月15日挂牌。公司上市引入4名基石投资者，包括徐州经开区(香港)、Harvest、TradArt Investment SP及Mobilewise，合共认购2.35亿元公司股份。","content":"<html><body><p>生物医药公司3D MEDICINES-B(01244.HK)公布招股详情，拟全球发售1,635万股，香港公开发售占一成，国际发售占九成。招股价介乎每股22.96至26.24元。每手500股计，一手入场费13,252.23元。该股今日(11月29日)起招股，下周三(12月7日)中午截止，预期将于12月15日挂牌。联席保荐人为中金及<a href=\"https://laohu8.com/S/601066\">中信建投</a>国际。公司上市引入4名基石投资者，包括徐州经开区(香港)、Harvest、TradArt Investment SP及Mobilewise，合共认购2.35亿元公司股份。如以招股价中位数24.6元计，公司上市料净集资约2.45亿元，当中约90%主要用于产品和候选药物的研发、监管备案及商业化；约10%将用于一般企业及营运资金用途。(jl/w)~阿思达克财经新闻网址: www.aastocks.com</p></body></html>","source":"aastocks","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>《新股消息》3D MEDICINES-B(01244.HK)今起招股 一手入场费13,252.23元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n《新股消息》3D MEDICINES-B(01244.HK)今起招股 一手入场费13,252.23元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-11-29 08:27 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1229684&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0><strong>AAFN</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>生物医药公司3D MEDICINES-B(01244.HK)公布招股详情，拟全球发售1,635万股，香港公开发售占一成，国际发售占九成。招股价介乎每股22.96至26.24元。每手500股计，一手入场费13,252.23元。该股今日(11月29日)起招股，下周三(12月7日)中午截止，预期将于12月15日挂牌。联席保荐人为中金及中信建投国际。公司上市引入4名基石投资者，包括徐州经开区(香港)、...</p>\n\n<a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1229684&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","LU0043850808.USD":"HSBC GIF ASIA EX JAPAN EQUITY \"AD\" INC","LU0873338254.USD":"FULLERTON LUX FUNDS - ASIA GROWTH & INCOME EQUITIE \"I\" (USD) INC","BK1131":"金融交易所和数据","LU0577902538.SGD":"Fullerton Lux Funds - Asia Growth and Income Equities A Acc SGD","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0577902611.USD":"FULLERTON LUX FUNDS - ASIA GROWTH & INCOME EQUITIE \"A\" (USD) ACC","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","LU0577902454.USD":"FULLERTON LUX FUNDS - ASIA GROWTH & INCOME EQUITIE \"I\" (USD) ACC","LU0577902371.SGD":"FULLERTON LUX FUNDS - ASIA GROWTH & INCOME EQUITIE \"I\" (SGD) ACC","LU0456846285.SGD":"JPMorgan Funds - Greater China A (acc) SGD","SG9999002463.SGD":"LionGlobal China Growth SGD","LU1044876610.USD":"THREADNEEDLE (LUX) ASIAN CONTRARIAN EQUITY \"ZU\" (USD) ACC","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","LU0048597586.USD":"富达亚洲焦点A","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","LU1642822792.SGD":"THREADNEEDLE (LUX) ASIAN CONTRARIAN EQUITY \"A\" (SGD) ACC","LU1044874839.SGD":"THREADNEEDLE (LUX) ASIAN CONTRARIAN EQUITY \"AGH\" (SGDHDG) ACC","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","BK1521":"挪威政府全球养老基金持仓","LU1044875133.USD":"天利亚洲反向股票 AU Acc","01244":"思路迪医药股份","LU0327786744.USD":"Janus Henderson Horizon China Opportunities A2 USD","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","00388":"香港交易所","LU0211977185.USD":"EASTSPRING INVESTMENTS GREATER CHINA EQUITY \"A\" ACC","LU0577902298.EUR":"FULLERTON LUX FUNDS - ASIA GROWTH & INCOME EQUITIE \"I\" (EUR) ACC","BK1589":"北水核心资产","LU0140636845.USD":"施罗德大中华区股票A Acc","LU0251144936.SGD":"Fidelity Sustainable Asia Equity A-SGD"},"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1229684&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","is_english":false,"share_image_url":"https://static.laohu8.com/51f6b9126f36f92bbf92982596066e5a","article_id":"2287545465","content_text":"生物医药公司3D MEDICINES-B(01244.HK)公布招股详情，拟全球发售1,635万股，香港公开发售占一成，国际发售占九成。招股价介乎每股22.96至26.24元。每手500股计，一手入场费13,252.23元。该股今日(11月29日)起招股，下周三(12月7日)中午截止，预期将于12月15日挂牌。联席保荐人为中金及中信建投国际。公司上市引入4名基石投资者，包括徐州经开区(香港)、Harvest、TradArt Investment SP及Mobilewise，合共认购2.35亿元公司股份。如以招股价中位数24.6元计，公司上市料净集资约2.45亿元，当中约90%主要用于产品和候选药物的研发、监管备案及商业化；约10%将用于一般企业及营运资金用途。(jl/w)~阿思达克财经新闻网址: www.aastocks.com","news_type":1,"symbols_score_info":{"00388":0.9,"01244":1}},"isVote":1,"tweetType":1,"viewCount":3350,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":620870046,"gmtCreate":1669690798186,"gmtModify":1669690799728,"author":{"id":"4130472326487360","authorId":"4130472326487360","name":"Bek Smith","avatar":"https://static.tigerbbs.com/da802faf6741ad7a08c0290f82b414cc","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4130472326487360","idStr":"4130472326487360"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/620870046","repostId":"2287254564","repostType":2,"repost":{"id":"2287254564","kind":"highlight","weMediaInfo":{"introduction":"凤凰网港股","home_visible":1,"media_name":"凤凰网港股","id":"1002821290","head_image":"https://static.tigerbbs.com/b6fb647077f1ce46dc341fc35c26e817"},"pubTimestamp":1669681789,"share":"https://www.laohu8.com/m/news/2287254564?lang=zh_CN&edition=full","pubTime":"2022-11-29 08:29","market":"us","language":"zh","title":"【新股IPO】3D MEDICINES-B(01244)今起招股 入场费13252.23港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2287254564","media":"凤凰网港股","summary":"3D MEDICINES-B今起招股，拟全球发售1635万股，其中，香港发售占10%，国际发售占90%，另有超额配股权15%。每股发售价介乎22.96-26.24港元，每手500股，入场费13252.23港元；中金公司及中信建投国际为联席保荐人；该股份预期将于12月15日挂牌上市。据悉，3D MEDICINES是一家成立于2014年的生物医药公司，致力于为癌症患者，尤其是那些需要长期治疗的患者研发肿瘤药物。","content":"<html><body><p>3D MEDICINES-B(01244)今起招股，拟全球发售1635万股，其中，香港发售占10%，国际发售占90%，另有超额配股权15%。每股发售价介乎22.96-26.24港元，每手500股，入场费13252.23港元；<a href=\"https://laohu8.com/S/601995\">中金公司</a>及<a href=\"https://laohu8.com/S/601066\">中信建投</a>国际为联席保荐人；该股份预期将于12月15日挂牌上市。据悉，3D MEDICINES是一家成立于2014年的生物医药公司，致力于为癌症患者，尤其是那些需要长期治疗的患者研发肿瘤药物。公司的核心业务模式是通过联合合作开发、许可引进及自主发现等方式，开发及商业化肿瘤产品及候选药物。已建立一条包含一款核心产品及11款候选药物的管线，其中核心产品恩沃利单抗(品牌名:恩维达)为支柱产品，已于2021年11月获批并于2021年12月商业化，另有7款其他候选药物处于 临床阶段。 所筹资金用途：约90%将主要用于公司产品和候选药物的研发、监管备案及商业化；约10%将用于公司的一般企业及营运资金用途。</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【新股IPO】3D MEDICINES-B(01244)今起招股 入场费13252.23港元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【新股IPO】3D MEDICINES-B(01244)今起招股 入场费13252.23港元\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1002821290\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/b6fb647077f1ce46dc341fc35c26e817);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">凤凰网港股 </p>\n<p class=\"h-time\">2022-11-29 08:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>3D MEDICINES-B(01244)今起招股，拟全球发售1635万股，其中，香港发售占10%，国际发售占90%，另有超额配股权15%。每股发售价介乎22.96-26.24港元，每手500股，入场费13252.23港元；<a href=\"https://laohu8.com/S/601995\">中金公司</a>及<a href=\"https://laohu8.com/S/601066\">中信建投</a>国际为联席保荐人；该股份预期将于12月15日挂牌上市。据悉，3D MEDICINES是一家成立于2014年的生物医药公司，致力于为癌症患者，尤其是那些需要长期治疗的患者研发肿瘤药物。公司的核心业务模式是通过联合合作开发、许可引进及自主发现等方式，开发及商业化肿瘤产品及候选药物。已建立一条包含一款核心产品及11款候选药物的管线，其中核心产品恩沃利单抗(品牌名:恩维达)为支柱产品，已于2021年11月获批并于2021年12月商业化，另有7款其他候选药物处于 临床阶段。 所筹资金用途：约90%将主要用于公司产品和候选药物的研发、监管备案及商业化；约10%将用于公司的一般企业及营运资金用途。</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IPO":"Renaissance IPO ETF","01244":"思路迪医药股份"},"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=62a79e0fe0fe0a2c4d3a7e8494242b53","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2287254564","content_text":"3D MEDICINES-B(01244)今起招股，拟全球发售1635万股，其中，香港发售占10%，国际发售占90%，另有超额配股权15%。每股发售价介乎22.96-26.24港元，每手500股，入场费13252.23港元；中金公司及中信建投国际为联席保荐人；该股份预期将于12月15日挂牌上市。据悉，3D MEDICINES是一家成立于2014年的生物医药公司，致力于为癌症患者，尤其是那些需要长期治疗的患者研发肿瘤药物。公司的核心业务模式是通过联合合作开发、许可引进及自主发现等方式，开发及商业化肿瘤产品及候选药物。已建立一条包含一款核心产品及11款候选药物的管线，其中核心产品恩沃利单抗(品牌名:恩维达)为支柱产品，已于2021年11月获批并于2021年12月商业化，另有7款其他候选药物处于 临床阶段。 所筹资金用途：约90%将主要用于公司产品和候选药物的研发、监管备案及商业化；约10%将用于公司的一般企业及营运资金用途。","news_type":1,"symbols_score_info":{"01244":1,"IPO":1}},"isVote":1,"tweetType":1,"viewCount":2672,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":620847528,"gmtCreate":1669690625865,"gmtModify":1669690627388,"author":{"id":"4130472326487360","authorId":"4130472326487360","name":"Bek Smith","avatar":"https://static.tigerbbs.com/da802faf6741ad7a08c0290f82b414cc","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4130472326487360","idStr":"4130472326487360"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/620847528","repostId":"1107729224","repostType":2,"repost":{"id":"1107729224","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1669684496,"share":"https://www.laohu8.com/m/news/1107729224?lang=zh_CN&edition=full","pubTime":"2022-11-29 09:14","market":"hk","language":"zh","title":"新股发售 | 3D MEDICINES-B今起招股，入场费13252.23港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1107729224","media":"老虎资讯综合","summary":"11月29日，3D MEDICINES-B发布公告，公司拟全球发售1635万股股份，其中中国香港发售股份163.5万股，国际发售股份1471.5万股，另有15%超额配股权；2022年11月29日至12","content":"<html><head></head><body><p>11月29日，<a href=\"https://laohu8.com/S/01244\">3D MEDICINES-B</a>发布公告，公司拟全球发售1635万股股份，其中中国香港发售股份163.5万股，国际发售股份1471.5万股，另有15%超额配股权；2022年11月29日至12月7日招股，预期定价日为12月7日；发售价将为每股发售股份22.96-26.24港元，每手买卖单位500股，入场费约13252.23港元；中金公司及中信建投国际为联席保荐人；预期股份将于2022年12月15日于联交所主板挂牌上市。</p><p><img src=\"https://static.tigerbbs.com/2c0be958a118bf20d9cd87db8c523bd9\" tg-width=\"897\" tg-height=\"709\" width=\"100%\" height=\"auto\"/></p><p><b>申购阶梯：</b></p><p>每手500股，入场费13252.23港元。</p><p>乙组门槛为200000万股，申购所需资金约5300891.97港元。</p><p><img src=\"https://static.tigerbbs.com/c92f15f2d5dc92f088705e284d6c494f\" tg-width=\"897\" tg-height=\"535\" width=\"100%\" height=\"auto\"/></p><p>集团是一家成立于2014年的生物医药公司，致力于为癌症患者，尤其是那些需要长期治疗的患者研发肿瘤药物。集团的核心业务模式是通过联合合作开发、许可引进及自主发现等方式，开发及商业化肿瘤产品及候选药物。集团计划于上市后进一步提升集团的内部发现能力及继续利用合作开发及许可引进模式开展针对更多适应症的临床试验造福慢性癌症患者。截至最后实际可行日期，集团已建立一条包含一款核心产品及11款候选药物的管线，其中核心产品恩沃利单抗(品牌名：恩维达®)为集团的支柱产品，已于2021年11月获批并于2021年12月商业化，另有七款其他候选药物处于临床阶段(包括集团已启动临床试验或已取得IND批准及正准备启动临床试验的候选药物)。</p><p>集团的核心产品恩沃利单抗是一款皮下注射PD-L1抗体，其已在中国获批用于治疗既往接受过治疗的微卫星高度不稳定(MSI-H)╱错配修复功能缺陷(dMMR)晚期实体瘤。截至最后实际可行日期，集团的核心产品仅获批用于这一适应症。根据弗若斯特沙利文的资料，截至最后实际可行日期，在中国有四名商业化同行及五名临床阶段同行就治疗MSI-H/dMMR肿瘤与核心产品竞争。集团于整个肿瘤市场面临来自现有产品及潜在候选药物(包括靶向PD-1/L1的单克隆及双特异性抗体)的激烈竞争，核心产品的市场机会可能很小，因为其靶向大多数目标适应症的晚期治疗。例如，MSI-H/ dMMR晚期实体瘤在中国的发病数于2021年约为14.61万例，预期于2030年将达到约18.6万例，且仅约50%的病例将接受一次以上治疗。</p><p>集团已订立基石投资协议，据此，基石投资者已同意在若干条件规限下按发售价认购以合共2.35亿港元发售股份。假设发售价为24.60港元(即本招股章程所载指示性发售价范围的中位数)，基石投资者将认购的发售股份总数为953.65万股发售股份。基石投资者包括徐州经济技术开发区(香港)投资有限公司、Harvest、TradArt Investment SP、以及Mobilewise。</p><p><img src=\"https://static.tigerbbs.com/65b7af483bb5bb129e17cb7a66844666\" tg-width=\"894\" tg-height=\"522\" width=\"100%\" height=\"auto\"/></p><p>假设超额配股权未获行使及发售价为每股24.60港元，集团估计公司将收取的全球发售所得款项净额合计约为2.45亿港元。集团目前拟将集团将从此次发售所收取的所得款项净额约90%主要用于集团产品和候选药物的研发、监管备案及商业化；及约10%将用于集团的一般企业及营运资金用途。</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>新股发售 | 3D MEDICINES-B今起招股，入场费13252.23港元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n新股发售 | 3D MEDICINES-B今起招股，入场费13252.23港元\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2022-11-29 09:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>11月29日，<a href=\"https://laohu8.com/S/01244\">3D MEDICINES-B</a>发布公告，公司拟全球发售1635万股股份，其中中国香港发售股份163.5万股，国际发售股份1471.5万股，另有15%超额配股权；2022年11月29日至12月7日招股，预期定价日为12月7日；发售价将为每股发售股份22.96-26.24港元，每手买卖单位500股，入场费约13252.23港元；中金公司及中信建投国际为联席保荐人；预期股份将于2022年12月15日于联交所主板挂牌上市。</p><p><img src=\"https://static.tigerbbs.com/2c0be958a118bf20d9cd87db8c523bd9\" tg-width=\"897\" tg-height=\"709\" width=\"100%\" height=\"auto\"/></p><p><b>申购阶梯：</b></p><p>每手500股，入场费13252.23港元。</p><p>乙组门槛为200000万股，申购所需资金约5300891.97港元。</p><p><img src=\"https://static.tigerbbs.com/c92f15f2d5dc92f088705e284d6c494f\" tg-width=\"897\" tg-height=\"535\" width=\"100%\" height=\"auto\"/></p><p>集团是一家成立于2014年的生物医药公司，致力于为癌症患者，尤其是那些需要长期治疗的患者研发肿瘤药物。集团的核心业务模式是通过联合合作开发、许可引进及自主发现等方式，开发及商业化肿瘤产品及候选药物。集团计划于上市后进一步提升集团的内部发现能力及继续利用合作开发及许可引进模式开展针对更多适应症的临床试验造福慢性癌症患者。截至最后实际可行日期，集团已建立一条包含一款核心产品及11款候选药物的管线，其中核心产品恩沃利单抗(品牌名：恩维达®)为集团的支柱产品，已于2021年11月获批并于2021年12月商业化，另有七款其他候选药物处于临床阶段(包括集团已启动临床试验或已取得IND批准及正准备启动临床试验的候选药物)。</p><p>集团的核心产品恩沃利单抗是一款皮下注射PD-L1抗体，其已在中国获批用于治疗既往接受过治疗的微卫星高度不稳定(MSI-H)╱错配修复功能缺陷(dMMR)晚期实体瘤。截至最后实际可行日期，集团的核心产品仅获批用于这一适应症。根据弗若斯特沙利文的资料，截至最后实际可行日期，在中国有四名商业化同行及五名临床阶段同行就治疗MSI-H/dMMR肿瘤与核心产品竞争。集团于整个肿瘤市场面临来自现有产品及潜在候选药物(包括靶向PD-1/L1的单克隆及双特异性抗体)的激烈竞争，核心产品的市场机会可能很小，因为其靶向大多数目标适应症的晚期治疗。例如，MSI-H/ dMMR晚期实体瘤在中国的发病数于2021年约为14.61万例，预期于2030年将达到约18.6万例，且仅约50%的病例将接受一次以上治疗。</p><p>集团已订立基石投资协议，据此，基石投资者已同意在若干条件规限下按发售价认购以合共2.35亿港元发售股份。假设发售价为24.60港元(即本招股章程所载指示性发售价范围的中位数)，基石投资者将认购的发售股份总数为953.65万股发售股份。基石投资者包括徐州经济技术开发区(香港)投资有限公司、Harvest、TradArt Investment SP、以及Mobilewise。</p><p><img src=\"https://static.tigerbbs.com/65b7af483bb5bb129e17cb7a66844666\" tg-width=\"894\" tg-height=\"522\" width=\"100%\" height=\"auto\"/></p><p>假设超额配股权未获行使及发售价为每股24.60港元，集团估计公司将收取的全球发售所得款项净额合计约为2.45亿港元。集团目前拟将集团将从此次发售所收取的所得款项净额约90%主要用于集团产品和候选药物的研发、监管备案及商业化；及约10%将用于集团的一般企业及营运资金用途。</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/26d35a88c8d9d9d46abd395d2bd24396","relate_stocks":{"01244":"思路迪医药股份"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1107729224","content_text":"11月29日，3D MEDICINES-B发布公告，公司拟全球发售1635万股股份，其中中国香港发售股份163.5万股，国际发售股份1471.5万股，另有15%超额配股权；2022年11月29日至12月7日招股，预期定价日为12月7日；发售价将为每股发售股份22.96-26.24港元，每手买卖单位500股，入场费约13252.23港元；中金公司及中信建投国际为联席保荐人；预期股份将于2022年12月15日于联交所主板挂牌上市。申购阶梯：每手500股，入场费13252.23港元。乙组门槛为200000万股，申购所需资金约5300891.97港元。集团是一家成立于2014年的生物医药公司，致力于为癌症患者，尤其是那些需要长期治疗的患者研发肿瘤药物。集团的核心业务模式是通过联合合作开发、许可引进及自主发现等方式，开发及商业化肿瘤产品及候选药物。集团计划于上市后进一步提升集团的内部发现能力及继续利用合作开发及许可引进模式开展针对更多适应症的临床试验造福慢性癌症患者。截至最后实际可行日期，集团已建立一条包含一款核心产品及11款候选药物的管线，其中核心产品恩沃利单抗(品牌名：恩维达®)为集团的支柱产品，已于2021年11月获批并于2021年12月商业化，另有七款其他候选药物处于临床阶段(包括集团已启动临床试验或已取得IND批准及正准备启动临床试验的候选药物)。集团的核心产品恩沃利单抗是一款皮下注射PD-L1抗体，其已在中国获批用于治疗既往接受过治疗的微卫星高度不稳定(MSI-H)╱错配修复功能缺陷(dMMR)晚期实体瘤。截至最后实际可行日期，集团的核心产品仅获批用于这一适应症。根据弗若斯特沙利文的资料，截至最后实际可行日期，在中国有四名商业化同行及五名临床阶段同行就治疗MSI-H/dMMR肿瘤与核心产品竞争。集团于整个肿瘤市场面临来自现有产品及潜在候选药物(包括靶向PD-1/L1的单克隆及双特异性抗体)的激烈竞争，核心产品的市场机会可能很小，因为其靶向大多数目标适应症的晚期治疗。例如，MSI-H/ dMMR晚期实体瘤在中国的发病数于2021年约为14.61万例，预期于2030年将达到约18.6万例，且仅约50%的病例将接受一次以上治疗。集团已订立基石投资协议，据此，基石投资者已同意在若干条件规限下按发售价认购以合共2.35亿港元发售股份。假设发售价为24.60港元(即本招股章程所载指示性发售价范围的中位数)，基石投资者将认购的发售股份总数为953.65万股发售股份。基石投资者包括徐州经济技术开发区(香港)投资有限公司、Harvest、TradArt Investment SP、以及Mobilewise。假设超额配股权未获行使及发售价为每股24.60港元，集团估计公司将收取的全球发售所得款项净额合计约为2.45亿港元。集团目前拟将集团将从此次发售所收取的所得款项净额约90%主要用于集团产品和候选药物的研发、监管备案及商业化；及约10%将用于集团的一般企业及营运资金用途。","news_type":1,"symbols_score_info":{"01244":0.9}},"isVote":1,"tweetType":1,"viewCount":2773,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":667484132,"gmtCreate":1669088621326,"gmtModify":1669088625385,"author":{"id":"4130472326487360","authorId":"4130472326487360","name":"Bek Smith","avatar":"https://static.tigerbbs.com/da802faf6741ad7a08c0290f82b414cc","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4130472326487360","idStr":"4130472326487360"},"themes":[],"htmlText":"Woow going cool🔥😀","listText":"Woow going cool🔥😀","text":"Woow going cool🔥😀","images":[{"img":"https://static.tigerbbs.com/2f60c2d5ef40949bb95fa65ace885c5b","width":"1080","height":"2182"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/667484132","isVote":1,"tweetType":1,"viewCount":2328,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":667416640,"gmtCreate":1669083860080,"gmtModify":1669084106426,"author":{"id":"4130472326487360","authorId":"4130472326487360","name":"Bek Smith","avatar":"https://static.tigerbbs.com/da802faf6741ad7a08c0290f82b414cc","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4130472326487360","idStr":"4130472326487360"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/667416640","repostId":"667438230","repostType":1,"repost":{"id":667438230,"gmtCreate":1669079087421,"gmtModify":1669082726401,"author":{"id":"3463446769405484","authorId":"3463446769405484","name":"零点博弈资本","avatar":"https://static.tigerbbs.com/4872d62b52bc24d392619a9db00f4808","crmLevel":8,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3463446769405484","idStr":"3463446769405484"},"themes":[],"htmlText":"NQ100的首位度，越来越分化了，但只要一哥二哥稳如老狗，就问题不大！","listText":"NQ100的首位度，越来越分化了，但只要一哥二哥稳如老狗，就问题不大！","text":"NQ100的首位度，越来越分化了，但只要一哥二哥稳如老狗，就问题不大！","images":[{"img":"https://static.tigerbbs.com/ff2c4b6715af8272f3ecb153cc130926","width":"1080","height":"2185"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/667438230","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":953,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":667392107,"gmtCreate":1668563173109,"gmtModify":1668564549648,"author":{"id":"4130472326487360","authorId":"4130472326487360","name":"Bek Smith","avatar":"https://static.tigerbbs.com/da802faf6741ad7a08c0290f82b414cc","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4130472326487360","idStr":"4130472326487360"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/667392107","repostId":"667947871","repostType":1,"repost":{"id":667947871,"gmtCreate":1668525289093,"gmtModify":1668525290333,"author":{"id":"3570511940076236","authorId":"3570511940076236","name":"AdaMao","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3570511940076236","idStr":"3570511940076236"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BBBY\">$3B家居(BBBY)$&nbsp;</a>想问下大家，这玩意还有救吗？我在山顶入的，现在就剩一条破裤衩了，还有必要留着吗？","listText":"<a href=\"https://laohu8.com/S/BBBY\">$3B家居(BBBY)$&nbsp;</a>想问下大家，这玩意还有救吗？我在山顶入的，现在就剩一条破裤衩了，还有必要留着吗？","text":"$3B家居(BBBY)$ 想问下大家，这玩意还有救吗？我在山顶入的，现在就剩一条破裤衩了，还有必要留着吗？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/667947871","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":833,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":629384276,"gmtCreate":1670270184796,"gmtModify":1670270186308,"author":{"id":"4130472326487360","authorId":"4130472326487360","name":"Bek Smith","avatar":"https://static.tigerbbs.com/da802faf6741ad7a08c0290f82b414cc","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4130472326487360","idStr":"4130472326487360"},"themes":[],"htmlText":"👍👍👍","listText":"👍👍👍","text":"👍👍👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/629384276","isVote":1,"tweetType":1,"viewCount":2394,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":629990197,"gmtCreate":1670182306119,"gmtModify":1670182307678,"author":{"id":"4130472326487360","authorId":"4130472326487360","name":"Bek Smith","avatar":"https://static.tigerbbs.com/da802faf6741ad7a08c0290f82b414cc","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4130472326487360","idStr":"4130472326487360"},"themes":[],"htmlText":"👍👍👍👍","listText":"👍👍👍👍","text":"👍👍👍👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/629990197","isVote":1,"tweetType":1,"viewCount":2413,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":629052879,"gmtCreate":1670121696591,"gmtModify":1670121698074,"author":{"id":"4130472326487360","authorId":"4130472326487360","name":"Bek Smith","avatar":"https://static.tigerbbs.com/da802faf6741ad7a08c0290f82b414cc","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4130472326487360","idStr":"4130472326487360"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/629052879","isVote":1,"tweetType":1,"viewCount":2167,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":629052153,"gmtCreate":1670121682273,"gmtModify":1670121683778,"author":{"id":"4130472326487360","authorId":"4130472326487360","name":"Bek Smith","avatar":"https://static.tigerbbs.com/da802faf6741ad7a08c0290f82b414cc","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4130472326487360","idStr":"4130472326487360"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/629052153","isVote":1,"tweetType":1,"viewCount":1607,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":620879931,"gmtCreate":1669691002723,"gmtModify":1669691006678,"author":{"id":"4130472326487360","authorId":"4130472326487360","name":"Bek Smith","avatar":"https://static.tigerbbs.com/da802faf6741ad7a08c0290f82b414cc","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4130472326487360","idStr":"4130472326487360"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/620879931","repostId":"2287354144","repostType":2,"repost":{"id":"2287354144","kind":"news","pubTimestamp":1669674367,"share":"https://www.laohu8.com/m/news/2287354144?lang=zh_CN&edition=full","pubTime":"2022-11-29 06:26","market":"sh","language":"zh","title":"思路迪申请通过香港IPO发行1635万股股票","url":"https://stock-news.laohu8.com/highlight/detail?id=2287354144","media":"媒体滚动","summary":"思路迪（3D Medicines）在港交所公告称，申请通过香港IPO发行1635万股股票，股票发行价指导区间为每股22.96-26.24港元，预计12月15日将开始交易。","content":"<html><body><p>思路迪（3D Medicines）在港交所公告称，申请通过香港IPO发行1635万股股票，股票发行价指导区间为每股22.96-26.24港元，预计12月15日将开始交易。</p></body></html>","source":"sina_symbol","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>思路迪申请通过香港IPO发行1635万股股票</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n思路迪申请通过香港IPO发行1635万股股票\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-11-29 06:26 北京时间&nbsp;&nbsp;&nbsp;<a href=https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/7x24/2022-11-29/doc-imqmmthc6355254.shtml><strong>媒体滚动</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>思路迪（3D Medicines）在港交所公告称，申请通过香港IPO发行1635万股股票，股票发行价指导区间为每股22.96-26.24港元，预计12月15日将开始交易。</p>\n\n<a href=\"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/7x24/2022-11-29/doc-imqmmthc6355254.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IPO":"Renaissance IPO ETF","01244":"思路迪医药股份"},"source_url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/7x24/2022-11-29/doc-imqmmthc6355254.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2287354144","content_text":"思路迪（3D Medicines）在港交所公告称，申请通过香港IPO发行1635万股股票，股票发行价指导区间为每股22.96-26.24港元，预计12月15日将开始交易。","news_type":1,"symbols_score_info":{"01244":1,"IPO":1}},"isVote":1,"tweetType":1,"viewCount":2677,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":620870264,"gmtCreate":1669690966158,"gmtModify":1669690967697,"author":{"id":"4130472326487360","authorId":"4130472326487360","name":"Bek Smith","avatar":"https://static.tigerbbs.com/da802faf6741ad7a08c0290f82b414cc","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4130472326487360","idStr":"4130472326487360"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/620870264","repostId":"2287453885","repostType":2,"isVote":1,"tweetType":1,"viewCount":3110,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":620870130,"gmtCreate":1669690916320,"gmtModify":1669690919930,"author":{"id":"4130472326487360","authorId":"4130472326487360","name":"Bek Smith","avatar":"https://static.tigerbbs.com/da802faf6741ad7a08c0290f82b414cc","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4130472326487360","idStr":"4130472326487360"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/620870130","repostId":"2287545465","repostType":2,"repost":{"id":"2287545465","kind":"news","pubTimestamp":1669681671,"share":"https://www.laohu8.com/m/news/2287545465?lang=zh_CN&edition=full","pubTime":"2022-11-29 08:27","market":"us","language":"zh","title":"《新股消息》3D MEDICINES-B(01244.HK)今起招股 一手入场费13,252.23元","url":"https://stock-news.laohu8.com/highlight/detail?id=2287545465","media":"AAFN","summary":"生物医药公司3D MEDICINES-B公布招股详情，拟全球发售1,635万股，香港公开发售占一成，国际发售占九成。招股价介乎每股22.96至26.24元。每手500股计，一手入场费13,252.23元。该股今日起招股，下周三中午截止，预期将于12月15日挂牌。公司上市引入4名基石投资者，包括徐州经开区(香港)、Harvest、TradArt Investment SP及Mobilewise，合共认购2.35亿元公司股份。","content":"<html><body><p>生物医药公司3D MEDICINES-B(01244.HK)公布招股详情，拟全球发售1,635万股，香港公开发售占一成，国际发售占九成。招股价介乎每股22.96至26.24元。每手500股计，一手入场费13,252.23元。该股今日(11月29日)起招股，下周三(12月7日)中午截止，预期将于12月15日挂牌。联席保荐人为中金及<a href=\"https://laohu8.com/S/601066\">中信建投</a>国际。公司上市引入4名基石投资者，包括徐州经开区(香港)、Harvest、TradArt Investment SP及Mobilewise，合共认购2.35亿元公司股份。如以招股价中位数24.6元计，公司上市料净集资约2.45亿元，当中约90%主要用于产品和候选药物的研发、监管备案及商业化；约10%将用于一般企业及营运资金用途。(jl/w)~阿思达克财经新闻网址: www.aastocks.com</p></body></html>","source":"aastocks","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>《新股消息》3D MEDICINES-B(01244.HK)今起招股 一手入场费13,252.23元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n《新股消息》3D MEDICINES-B(01244.HK)今起招股 一手入场费13,252.23元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-11-29 08:27 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1229684&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0><strong>AAFN</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>生物医药公司3D MEDICINES-B(01244.HK)公布招股详情，拟全球发售1,635万股，香港公开发售占一成，国际发售占九成。招股价介乎每股22.96至26.24元。每手500股计，一手入场费13,252.23元。该股今日(11月29日)起招股，下周三(12月7日)中午截止，预期将于12月15日挂牌。联席保荐人为中金及中信建投国际。公司上市引入4名基石投资者，包括徐州经开区(香港)、...</p>\n\n<a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1229684&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","LU0043850808.USD":"HSBC GIF ASIA EX JAPAN EQUITY \"AD\" INC","LU0873338254.USD":"FULLERTON LUX FUNDS - ASIA GROWTH & INCOME EQUITIE \"I\" (USD) INC","BK1131":"金融交易所和数据","LU0577902538.SGD":"Fullerton Lux Funds - Asia Growth and Income Equities A Acc SGD","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0577902611.USD":"FULLERTON LUX FUNDS - ASIA GROWTH & INCOME EQUITIE \"A\" (USD) ACC","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","LU0577902454.USD":"FULLERTON LUX FUNDS - ASIA GROWTH & INCOME EQUITIE \"I\" (USD) ACC","LU0577902371.SGD":"FULLERTON LUX FUNDS - ASIA GROWTH & INCOME EQUITIE \"I\" (SGD) ACC","LU0456846285.SGD":"JPMorgan Funds - Greater China A (acc) SGD","SG9999002463.SGD":"LionGlobal China Growth SGD","LU1044876610.USD":"THREADNEEDLE (LUX) ASIAN CONTRARIAN EQUITY \"ZU\" (USD) ACC","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","LU0048597586.USD":"富达亚洲焦点A","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","LU1642822792.SGD":"THREADNEEDLE (LUX) ASIAN CONTRARIAN EQUITY \"A\" (SGD) ACC","LU1044874839.SGD":"THREADNEEDLE (LUX) ASIAN CONTRARIAN EQUITY \"AGH\" (SGDHDG) ACC","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","BK1521":"挪威政府全球养老基金持仓","LU1044875133.USD":"天利亚洲反向股票 AU Acc","01244":"思路迪医药股份","LU0327786744.USD":"Janus Henderson Horizon China Opportunities A2 USD","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","00388":"香港交易所","LU0211977185.USD":"EASTSPRING INVESTMENTS GREATER CHINA EQUITY \"A\" ACC","LU0577902298.EUR":"FULLERTON LUX FUNDS - ASIA GROWTH & INCOME EQUITIE \"I\" (EUR) ACC","BK1589":"北水核心资产","LU0140636845.USD":"施罗德大中华区股票A Acc","LU0251144936.SGD":"Fidelity Sustainable Asia Equity A-SGD"},"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1229684&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","is_english":false,"share_image_url":"https://static.laohu8.com/51f6b9126f36f92bbf92982596066e5a","article_id":"2287545465","content_text":"生物医药公司3D MEDICINES-B(01244.HK)公布招股详情，拟全球发售1,635万股，香港公开发售占一成，国际发售占九成。招股价介乎每股22.96至26.24元。每手500股计，一手入场费13,252.23元。该股今日(11月29日)起招股，下周三(12月7日)中午截止，预期将于12月15日挂牌。联席保荐人为中金及中信建投国际。公司上市引入4名基石投资者，包括徐州经开区(香港)、Harvest、TradArt Investment SP及Mobilewise，合共认购2.35亿元公司股份。如以招股价中位数24.6元计，公司上市料净集资约2.45亿元，当中约90%主要用于产品和候选药物的研发、监管备案及商业化；约10%将用于一般企业及营运资金用途。(jl/w)~阿思达克财经新闻网址: www.aastocks.com","news_type":1,"symbols_score_info":{"00388":0.9,"01244":1}},"isVote":1,"tweetType":1,"viewCount":3350,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":620870046,"gmtCreate":1669690798186,"gmtModify":1669690799728,"author":{"id":"4130472326487360","authorId":"4130472326487360","name":"Bek Smith","avatar":"https://static.tigerbbs.com/da802faf6741ad7a08c0290f82b414cc","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4130472326487360","idStr":"4130472326487360"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/620870046","repostId":"2287254564","repostType":2,"repost":{"id":"2287254564","kind":"highlight","weMediaInfo":{"introduction":"凤凰网港股","home_visible":1,"media_name":"凤凰网港股","id":"1002821290","head_image":"https://static.tigerbbs.com/b6fb647077f1ce46dc341fc35c26e817"},"pubTimestamp":1669681789,"share":"https://www.laohu8.com/m/news/2287254564?lang=zh_CN&edition=full","pubTime":"2022-11-29 08:29","market":"us","language":"zh","title":"【新股IPO】3D MEDICINES-B(01244)今起招股 入场费13252.23港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2287254564","media":"凤凰网港股","summary":"3D MEDICINES-B今起招股，拟全球发售1635万股，其中，香港发售占10%，国际发售占90%，另有超额配股权15%。每股发售价介乎22.96-26.24港元，每手500股，入场费13252.23港元；中金公司及中信建投国际为联席保荐人；该股份预期将于12月15日挂牌上市。据悉，3D MEDICINES是一家成立于2014年的生物医药公司，致力于为癌症患者，尤其是那些需要长期治疗的患者研发肿瘤药物。","content":"<html><body><p>3D MEDICINES-B(01244)今起招股，拟全球发售1635万股，其中，香港发售占10%，国际发售占90%，另有超额配股权15%。每股发售价介乎22.96-26.24港元，每手500股，入场费13252.23港元；<a href=\"https://laohu8.com/S/601995\">中金公司</a>及<a href=\"https://laohu8.com/S/601066\">中信建投</a>国际为联席保荐人；该股份预期将于12月15日挂牌上市。据悉，3D MEDICINES是一家成立于2014年的生物医药公司，致力于为癌症患者，尤其是那些需要长期治疗的患者研发肿瘤药物。公司的核心业务模式是通过联合合作开发、许可引进及自主发现等方式，开发及商业化肿瘤产品及候选药物。已建立一条包含一款核心产品及11款候选药物的管线，其中核心产品恩沃利单抗(品牌名:恩维达)为支柱产品，已于2021年11月获批并于2021年12月商业化，另有7款其他候选药物处于 临床阶段。 所筹资金用途：约90%将主要用于公司产品和候选药物的研发、监管备案及商业化；约10%将用于公司的一般企业及营运资金用途。</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【新股IPO】3D MEDICINES-B(01244)今起招股 入场费13252.23港元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【新股IPO】3D MEDICINES-B(01244)今起招股 入场费13252.23港元\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1002821290\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/b6fb647077f1ce46dc341fc35c26e817);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">凤凰网港股 </p>\n<p class=\"h-time\">2022-11-29 08:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>3D MEDICINES-B(01244)今起招股，拟全球发售1635万股，其中，香港发售占10%，国际发售占90%，另有超额配股权15%。每股发售价介乎22.96-26.24港元，每手500股，入场费13252.23港元；<a href=\"https://laohu8.com/S/601995\">中金公司</a>及<a href=\"https://laohu8.com/S/601066\">中信建投</a>国际为联席保荐人；该股份预期将于12月15日挂牌上市。据悉，3D MEDICINES是一家成立于2014年的生物医药公司，致力于为癌症患者，尤其是那些需要长期治疗的患者研发肿瘤药物。公司的核心业务模式是通过联合合作开发、许可引进及自主发现等方式，开发及商业化肿瘤产品及候选药物。已建立一条包含一款核心产品及11款候选药物的管线，其中核心产品恩沃利单抗(品牌名:恩维达)为支柱产品，已于2021年11月获批并于2021年12月商业化，另有7款其他候选药物处于 临床阶段。 所筹资金用途：约90%将主要用于公司产品和候选药物的研发、监管备案及商业化；约10%将用于公司的一般企业及营运资金用途。</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IPO":"Renaissance IPO ETF","01244":"思路迪医药股份"},"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=62a79e0fe0fe0a2c4d3a7e8494242b53","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2287254564","content_text":"3D MEDICINES-B(01244)今起招股，拟全球发售1635万股，其中，香港发售占10%，国际发售占90%，另有超额配股权15%。每股发售价介乎22.96-26.24港元，每手500股，入场费13252.23港元；中金公司及中信建投国际为联席保荐人；该股份预期将于12月15日挂牌上市。据悉，3D MEDICINES是一家成立于2014年的生物医药公司，致力于为癌症患者，尤其是那些需要长期治疗的患者研发肿瘤药物。公司的核心业务模式是通过联合合作开发、许可引进及自主发现等方式，开发及商业化肿瘤产品及候选药物。已建立一条包含一款核心产品及11款候选药物的管线，其中核心产品恩沃利单抗(品牌名:恩维达)为支柱产品，已于2021年11月获批并于2021年12月商业化，另有7款其他候选药物处于 临床阶段。 所筹资金用途：约90%将主要用于公司产品和候选药物的研发、监管备案及商业化；约10%将用于公司的一般企业及营运资金用途。","news_type":1,"symbols_score_info":{"01244":1,"IPO":1}},"isVote":1,"tweetType":1,"viewCount":2672,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":620847528,"gmtCreate":1669690625865,"gmtModify":1669690627388,"author":{"id":"4130472326487360","authorId":"4130472326487360","name":"Bek Smith","avatar":"https://static.tigerbbs.com/da802faf6741ad7a08c0290f82b414cc","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4130472326487360","idStr":"4130472326487360"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/620847528","repostId":"1107729224","repostType":2,"repost":{"id":"1107729224","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1669684496,"share":"https://www.laohu8.com/m/news/1107729224?lang=zh_CN&edition=full","pubTime":"2022-11-29 09:14","market":"hk","language":"zh","title":"新股发售 | 3D MEDICINES-B今起招股，入场费13252.23港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1107729224","media":"老虎资讯综合","summary":"11月29日，3D MEDICINES-B发布公告，公司拟全球发售1635万股股份，其中中国香港发售股份163.5万股，国际发售股份1471.5万股，另有15%超额配股权；2022年11月29日至12","content":"<html><head></head><body><p>11月29日，<a href=\"https://laohu8.com/S/01244\">3D MEDICINES-B</a>发布公告，公司拟全球发售1635万股股份，其中中国香港发售股份163.5万股，国际发售股份1471.5万股，另有15%超额配股权；2022年11月29日至12月7日招股，预期定价日为12月7日；发售价将为每股发售股份22.96-26.24港元，每手买卖单位500股，入场费约13252.23港元；中金公司及中信建投国际为联席保荐人；预期股份将于2022年12月15日于联交所主板挂牌上市。</p><p><img src=\"https://static.tigerbbs.com/2c0be958a118bf20d9cd87db8c523bd9\" tg-width=\"897\" tg-height=\"709\" width=\"100%\" height=\"auto\"/></p><p><b>申购阶梯：</b></p><p>每手500股，入场费13252.23港元。</p><p>乙组门槛为200000万股，申购所需资金约5300891.97港元。</p><p><img src=\"https://static.tigerbbs.com/c92f15f2d5dc92f088705e284d6c494f\" tg-width=\"897\" tg-height=\"535\" width=\"100%\" height=\"auto\"/></p><p>集团是一家成立于2014年的生物医药公司，致力于为癌症患者，尤其是那些需要长期治疗的患者研发肿瘤药物。集团的核心业务模式是通过联合合作开发、许可引进及自主发现等方式，开发及商业化肿瘤产品及候选药物。集团计划于上市后进一步提升集团的内部发现能力及继续利用合作开发及许可引进模式开展针对更多适应症的临床试验造福慢性癌症患者。截至最后实际可行日期，集团已建立一条包含一款核心产品及11款候选药物的管线，其中核心产品恩沃利单抗(品牌名：恩维达®)为集团的支柱产品，已于2021年11月获批并于2021年12月商业化，另有七款其他候选药物处于临床阶段(包括集团已启动临床试验或已取得IND批准及正准备启动临床试验的候选药物)。</p><p>集团的核心产品恩沃利单抗是一款皮下注射PD-L1抗体，其已在中国获批用于治疗既往接受过治疗的微卫星高度不稳定(MSI-H)╱错配修复功能缺陷(dMMR)晚期实体瘤。截至最后实际可行日期，集团的核心产品仅获批用于这一适应症。根据弗若斯特沙利文的资料，截至最后实际可行日期，在中国有四名商业化同行及五名临床阶段同行就治疗MSI-H/dMMR肿瘤与核心产品竞争。集团于整个肿瘤市场面临来自现有产品及潜在候选药物(包括靶向PD-1/L1的单克隆及双特异性抗体)的激烈竞争，核心产品的市场机会可能很小，因为其靶向大多数目标适应症的晚期治疗。例如，MSI-H/ dMMR晚期实体瘤在中国的发病数于2021年约为14.61万例，预期于2030年将达到约18.6万例，且仅约50%的病例将接受一次以上治疗。</p><p>集团已订立基石投资协议，据此，基石投资者已同意在若干条件规限下按发售价认购以合共2.35亿港元发售股份。假设发售价为24.60港元(即本招股章程所载指示性发售价范围的中位数)，基石投资者将认购的发售股份总数为953.65万股发售股份。基石投资者包括徐州经济技术开发区(香港)投资有限公司、Harvest、TradArt Investment SP、以及Mobilewise。</p><p><img src=\"https://static.tigerbbs.com/65b7af483bb5bb129e17cb7a66844666\" tg-width=\"894\" tg-height=\"522\" width=\"100%\" height=\"auto\"/></p><p>假设超额配股权未获行使及发售价为每股24.60港元，集团估计公司将收取的全球发售所得款项净额合计约为2.45亿港元。集团目前拟将集团将从此次发售所收取的所得款项净额约90%主要用于集团产品和候选药物的研发、监管备案及商业化；及约10%将用于集团的一般企业及营运资金用途。</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>新股发售 | 3D MEDICINES-B今起招股，入场费13252.23港元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n新股发售 | 3D MEDICINES-B今起招股，入场费13252.23港元\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2022-11-29 09:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>11月29日，<a href=\"https://laohu8.com/S/01244\">3D MEDICINES-B</a>发布公告，公司拟全球发售1635万股股份，其中中国香港发售股份163.5万股，国际发售股份1471.5万股，另有15%超额配股权；2022年11月29日至12月7日招股，预期定价日为12月7日；发售价将为每股发售股份22.96-26.24港元，每手买卖单位500股，入场费约13252.23港元；中金公司及中信建投国际为联席保荐人；预期股份将于2022年12月15日于联交所主板挂牌上市。</p><p><img src=\"https://static.tigerbbs.com/2c0be958a118bf20d9cd87db8c523bd9\" tg-width=\"897\" tg-height=\"709\" width=\"100%\" height=\"auto\"/></p><p><b>申购阶梯：</b></p><p>每手500股，入场费13252.23港元。</p><p>乙组门槛为200000万股，申购所需资金约5300891.97港元。</p><p><img src=\"https://static.tigerbbs.com/c92f15f2d5dc92f088705e284d6c494f\" tg-width=\"897\" tg-height=\"535\" width=\"100%\" height=\"auto\"/></p><p>集团是一家成立于2014年的生物医药公司，致力于为癌症患者，尤其是那些需要长期治疗的患者研发肿瘤药物。集团的核心业务模式是通过联合合作开发、许可引进及自主发现等方式，开发及商业化肿瘤产品及候选药物。集团计划于上市后进一步提升集团的内部发现能力及继续利用合作开发及许可引进模式开展针对更多适应症的临床试验造福慢性癌症患者。截至最后实际可行日期，集团已建立一条包含一款核心产品及11款候选药物的管线，其中核心产品恩沃利单抗(品牌名：恩维达®)为集团的支柱产品，已于2021年11月获批并于2021年12月商业化，另有七款其他候选药物处于临床阶段(包括集团已启动临床试验或已取得IND批准及正准备启动临床试验的候选药物)。</p><p>集团的核心产品恩沃利单抗是一款皮下注射PD-L1抗体，其已在中国获批用于治疗既往接受过治疗的微卫星高度不稳定(MSI-H)╱错配修复功能缺陷(dMMR)晚期实体瘤。截至最后实际可行日期，集团的核心产品仅获批用于这一适应症。根据弗若斯特沙利文的资料，截至最后实际可行日期，在中国有四名商业化同行及五名临床阶段同行就治疗MSI-H/dMMR肿瘤与核心产品竞争。集团于整个肿瘤市场面临来自现有产品及潜在候选药物(包括靶向PD-1/L1的单克隆及双特异性抗体)的激烈竞争，核心产品的市场机会可能很小，因为其靶向大多数目标适应症的晚期治疗。例如，MSI-H/ dMMR晚期实体瘤在中国的发病数于2021年约为14.61万例，预期于2030年将达到约18.6万例，且仅约50%的病例将接受一次以上治疗。</p><p>集团已订立基石投资协议，据此，基石投资者已同意在若干条件规限下按发售价认购以合共2.35亿港元发售股份。假设发售价为24.60港元(即本招股章程所载指示性发售价范围的中位数)，基石投资者将认购的发售股份总数为953.65万股发售股份。基石投资者包括徐州经济技术开发区(香港)投资有限公司、Harvest、TradArt Investment SP、以及Mobilewise。</p><p><img src=\"https://static.tigerbbs.com/65b7af483bb5bb129e17cb7a66844666\" tg-width=\"894\" tg-height=\"522\" width=\"100%\" height=\"auto\"/></p><p>假设超额配股权未获行使及发售价为每股24.60港元，集团估计公司将收取的全球发售所得款项净额合计约为2.45亿港元。集团目前拟将集团将从此次发售所收取的所得款项净额约90%主要用于集团产品和候选药物的研发、监管备案及商业化；及约10%将用于集团的一般企业及营运资金用途。</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/26d35a88c8d9d9d46abd395d2bd24396","relate_stocks":{"01244":"思路迪医药股份"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1107729224","content_text":"11月29日，3D MEDICINES-B发布公告，公司拟全球发售1635万股股份，其中中国香港发售股份163.5万股，国际发售股份1471.5万股，另有15%超额配股权；2022年11月29日至12月7日招股，预期定价日为12月7日；发售价将为每股发售股份22.96-26.24港元，每手买卖单位500股，入场费约13252.23港元；中金公司及中信建投国际为联席保荐人；预期股份将于2022年12月15日于联交所主板挂牌上市。申购阶梯：每手500股，入场费13252.23港元。乙组门槛为200000万股，申购所需资金约5300891.97港元。集团是一家成立于2014年的生物医药公司，致力于为癌症患者，尤其是那些需要长期治疗的患者研发肿瘤药物。集团的核心业务模式是通过联合合作开发、许可引进及自主发现等方式，开发及商业化肿瘤产品及候选药物。集团计划于上市后进一步提升集团的内部发现能力及继续利用合作开发及许可引进模式开展针对更多适应症的临床试验造福慢性癌症患者。截至最后实际可行日期，集团已建立一条包含一款核心产品及11款候选药物的管线，其中核心产品恩沃利单抗(品牌名：恩维达®)为集团的支柱产品，已于2021年11月获批并于2021年12月商业化，另有七款其他候选药物处于临床阶段(包括集团已启动临床试验或已取得IND批准及正准备启动临床试验的候选药物)。集团的核心产品恩沃利单抗是一款皮下注射PD-L1抗体，其已在中国获批用于治疗既往接受过治疗的微卫星高度不稳定(MSI-H)╱错配修复功能缺陷(dMMR)晚期实体瘤。截至最后实际可行日期，集团的核心产品仅获批用于这一适应症。根据弗若斯特沙利文的资料，截至最后实际可行日期，在中国有四名商业化同行及五名临床阶段同行就治疗MSI-H/dMMR肿瘤与核心产品竞争。集团于整个肿瘤市场面临来自现有产品及潜在候选药物(包括靶向PD-1/L1的单克隆及双特异性抗体)的激烈竞争，核心产品的市场机会可能很小，因为其靶向大多数目标适应症的晚期治疗。例如，MSI-H/ dMMR晚期实体瘤在中国的发病数于2021年约为14.61万例，预期于2030年将达到约18.6万例，且仅约50%的病例将接受一次以上治疗。集团已订立基石投资协议，据此，基石投资者已同意在若干条件规限下按发售价认购以合共2.35亿港元发售股份。假设发售价为24.60港元(即本招股章程所载指示性发售价范围的中位数)，基石投资者将认购的发售股份总数为953.65万股发售股份。基石投资者包括徐州经济技术开发区(香港)投资有限公司、Harvest、TradArt Investment SP、以及Mobilewise。假设超额配股权未获行使及发售价为每股24.60港元，集团估计公司将收取的全球发售所得款项净额合计约为2.45亿港元。集团目前拟将集团将从此次发售所收取的所得款项净额约90%主要用于集团产品和候选药物的研发、监管备案及商业化；及约10%将用于集团的一般企业及营运资金用途。","news_type":1,"symbols_score_info":{"01244":0.9}},"isVote":1,"tweetType":1,"viewCount":2773,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":667484132,"gmtCreate":1669088621326,"gmtModify":1669088625385,"author":{"id":"4130472326487360","authorId":"4130472326487360","name":"Bek Smith","avatar":"https://static.tigerbbs.com/da802faf6741ad7a08c0290f82b414cc","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"4130472326487360","idStr":"4130472326487360"},"themes":[],"htmlText":"Woow going cool🔥😀","listText":"Woow going cool🔥😀","text":"Woow going cool🔥😀","images":[{"img":"https://static.tigerbbs.com/2f60c2d5ef40949bb95fa65ace885c5b","width":"1080","height":"2182"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/667484132","isVote":1,"tweetType":1,"viewCount":2328,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"lives":[]}